Reduction of regulatory T cells in skin lesions but not in peripheral blood of patients with systemic scleroderma

被引:55
作者
Klein, S. [2 ]
Kretz, C. C. [2 ]
Ruland, V. [1 ]
Stumpf, C. [2 ]
Haust, M. [3 ]
Hartschuh, W. [4 ]
Hartmann, M. [4 ]
Enk, A. [4 ]
Suri-Payer, E. [2 ]
Oberle, N. [2 ]
Krammer, P. H. [2 ]
Kuhn, A. [1 ,2 ]
机构
[1] Univ Munster, Dept Dermatol, D-48149 Munster, Germany
[2] German Canc Res Ctr, Div Immunogenet, Tumorimmunol Program, D-6900 Heidelberg, Germany
[3] Univ Duesseldorf, Dept Dermatol, Dusseldorf, Germany
[4] Heidelberg Univ, Dept Dermatol, D-6900 Heidelberg, Germany
关键词
DEFECTIVE SUPPRESSOR FUNCTION; LOCALIZED SCLERODERMA; SCLEROSIS; BOSENTAN; HYPERTENSION; FREQUENCY; THICKNESS; SUBSETS; THERAPY; NUMBER;
D O I
10.1136/ard.2009.116525
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective To determine the frequency and suppressive capacity of regulatory T cells (T-reg) and their association with clinical parameters in patients with systemic scleroderma (SSc). Methods Peripheral blood from 25 patients with SSc, 15 patients with localised scleroderma (LS) and 29 healthy controls (HC) was studied. Analysis of CD4(+) forkhead box P3 (Foxp3)(+) and CD4(+) CD25(++) Foxp3(+) T-reg subpopulations was carried out by flow cytometry and cell proliferation was quantifi ed by H-3-thymidine incorporation. Quantitative analysis of T-reg was further performed in skin biopsies from 17 patients with SSc and 21 patients with LS using anti-CD4 and anti-Foxp3 monoclonal antibodies for immunohistochemistry. Results The frequency of CD4(+) Foxp3(+) and CD4(+) CD25(++) Foxp3(+) T-reg in peripheral blood from patients with SSc was not significantly different from that of patients with LS or HC. The suppressive capacity of CD4(+) CD25(++) T-reg in SSc was also found to be similar to that of HC. Phenotypic and functional data revealed no significant difference between the limited or diffuse form of SSc. Moreover, therapy with bosentan showed no significant effect on the frequency of T-reg during the course of the disease. However, the frequency of T-reg in skin lesions from patients with SSc or LS, determined as the percentage of CD4(+) cells expressing Foxp3 in the inflammatory infiltrate, was significantly reduced compared with other inflammatory skin diseases. Conclusion These results indicate that although the authors found no defect in the frequency or function of peripheral T-reg subpopulations, the reduction of CD4(+) Foxp3(+) T-reg in the skin of patients with SSc may be important in the pathogenesis of the disease.
引用
收藏
页码:1475 / 1481
页数:7
相关论文
共 44 条
[21]   High frequency of corticosteroid and immunosuppressive therapy in patients with systemic sclerosis despite limited evidence for efficacy [J].
Hunzelmann, Nicolas ;
Moinzadeh, Pia ;
Genth, Ekkehard ;
Krieg, Thomas ;
Lehmacher, Walter ;
Melchers, Inga ;
Meurer, Michael ;
Mueller-Ladner, Ulf ;
Olski, Thorsten M. ;
Pfeiffer, Christiane ;
Riemekasten, Gabriela ;
Schulze-Lohoff, Eckhard ;
Sunderkoetter, Cord ;
Weber, Manfred .
ARTHRITIS RESEARCH & THERAPY, 2009, 11 (02)
[22]   Bosentan regulates the expression of adhesion molecules on circulating T cells and serum soluble adhesion molecules in systemic sclerosis-associated pulmonary arterial hypertension [J].
Iannone, F. ;
Riccardi, M. T. ;
Guiducci, S. ;
Bizzoca, R. ;
Cinelli, M. ;
Matucci-Cerinic, M. ;
Lapadula, G. .
ANNALS OF THE RHEUMATIC DISEASES, 2008, 67 (08) :1121-1126
[23]   Endothelin receptor antagonism - Role in the treatment of pulmonary arterial hypertension related to scleroderma [J].
Kabunga, Peter ;
Coghlan, Gerry .
DRUGS, 2008, 68 (12) :1635-1645
[24]   Digital ulcers in systemic sclerosis - Prevention by treatment with bosentan, an oral endothelin receptor antagonist [J].
Korn, JH ;
Mayes, M ;
Cerinic, MM ;
Rainisio, M ;
Pope, J ;
Hachulla, E ;
Rich, E ;
Carpentier, P ;
Molitor, J ;
Seibold, JR ;
Hsu, V ;
Guillevin, L ;
Chatterjee, S ;
Peter, HH ;
Coppock, J ;
Herrick, A ;
Merkel, PA ;
Simms, R ;
Denton, CP ;
Furst, D ;
Nguyen, N ;
Gaitonde, M ;
Black, C .
ARTHRITIS AND RHEUMATISM, 2004, 50 (12) :3985-3993
[25]   EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR) [J].
Kowal-Bielecka, O. ;
Landewe, R. ;
Avouac, J. ;
Chwiesko, S. ;
Miniati, I. ;
Czirjak, L. ;
Clements, P. ;
Denton, C. ;
Farge, D. ;
Fligelstone, K. ;
Foeldvari, I. ;
Furst, D. E. ;
Mueller-Ladner, U. ;
Seibold, J. ;
Silver, R. M. ;
Takehara, K. ;
Toth, B. Garay ;
Tyndall, A. ;
Valentini, G. ;
van den Hoogen, F. ;
Wigley, F. ;
Zulian, F. ;
Matucci-Cerinic, Marco .
ANNALS OF THE RHEUMATIC DISEASES, 2009, 68 (05) :620-628
[26]   Defective suppressor function of human CD4+ CD25+ regulatory T cells in autoimmune polyglandular syndrome type II [J].
Kriegel, MA ;
Lohmann, T ;
Gabler, C ;
Blank, N ;
Kalden, JR ;
Lorenz, HM .
JOURNAL OF EXPERIMENTAL MEDICINE, 2004, 199 (09) :1285-1291
[27]   Effect of bosentan on skin fibrosis in patients with systemic sclerosis: a prospective, open-label, non-comparative trial [J].
Kuhn, Annegret ;
Haust, Merle ;
Ruland, Vincent ;
Weber, Ramona ;
Verde, Pablo ;
Felder, Gerd ;
Ohmann, Christian ;
Gensch, Kristina ;
Ruzicka, Thomas .
RHEUMATOLOGY, 2010, 49 (07) :1336-1345
[28]   CD4+CD25+ regulatory T cells in human lupus erythematosus [J].
Kuhn, Annegret ;
Beissert, Stefan ;
Krammer, Peter H. .
ARCHIVES OF DERMATOLOGICAL RESEARCH, 2009, 301 (01) :71-81
[29]   Multiple immuno-regulatory defects in type-1 diabetes [J].
Kukreja, A ;
Cost, G ;
Marker, J ;
Zhang, CH ;
Sun, Z ;
Lin-Su, K ;
Ten, S ;
Sanz, M ;
Exley, M ;
Wilson, B ;
Porcelli, S ;
Maclaren, N .
JOURNAL OF CLINICAL INVESTIGATION, 2002, 109 (01) :131-140
[30]  
Leitenberger JJ, 2009, ARCH DERMATOL, V145, P545, DOI 10.1001/archdermatol.2009.79